Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT01198899
• Date of registration: 31/08/2010
• Prospective Registration: No
• Primary sponsor: University Hospital, Ghent
• Public title: Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
• Scientific title: Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
• Date of first enrolment: July 2009
• Target sample size: 540
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT01198899
• Study type: Observational
• Study design: Observational Model: Cohort, Time Perspective: Prospective
• Phase: N/A

Countries of recruitment

Belgium

Contacts

• Name: Raymond Vanholder, MD, PhD
• Affiliation: University Hospital Ghent, Belgium

Key inclusion & exclusion criteria

Inclusion Criteria:

- All patients over 18 years undergoing a routine echocardiography in the participating
hospitals

- Both genders will be considered.

- Patients can be included if on 2D echocardiography the maximal septal wall thickness
> 13 mm and/or the posterior wall thickness > 13 mm. The limit for inclusion is kept
relatively low to detect early forms of Fabry cardiomyopathy.



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Left Ventricular Hypertrophy

Intervention(s)

Other: blood sampling

Primary Outcome(s)

Determination of the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography [Time Frame: At baseline T0]

Secondary ID(s)

2009/035

Source(s) of Monetary Support

Please refer to primary and secondary sponsors